Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 8/20 | 0.36 |
| ▸ | CTSB | P07858 | 6/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13016815 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4EHSD17B10CTSLCTSB | |
| SCHEMBL13016806 | 0.85 | EGLN2 (0.42) | ALDH1A1KDM4EHSD17B10EGLN2EGLN1 | |
| SCHEMBL3111586 | 0.85 | EGLN2 (0.42) | ALDH1A1KDM4EHSD17B10EGLN2EGLN1 | |
| SCHEMBL3780107 | 0.85 | CA12 (0.45) | ALDH1A1CTSLCTSB | |
| SCHEMBL13016822 | 0.85 | CA12 (0.45) | ALDH1A1CTSLCTSB | |
| SCHEMBL13016818 | 0.83 | TMEM97 (0.39) | ALDH1A1KDM4ECTSLCTSB | |
| SCHEMBL3104786 | 0.83 | TMEM97 (0.39) | ALDH1A1KDM4ECTSLCTSB | |
| SCHEMBL27613529 | 0.82 | KCNA5 (0.37) | ALDH1A1KDM4EHSD17B10CTSLCTSB | |
| SCHEMBL13016814 | 0.80 | CACNA2D1 (0.40) | CTSLCTSBSLC18A2EGLN2EGLN1 | |
| SCHEMBL3116572 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KDM4EHSD17B10CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | claimed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | claimed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| EP-1572627-A1 | DRUGS FOR CHRONIC PAIN | Nicox S.A. (FR) | 2005-09-14 | — | — | EP | claimed |
| WO-2004054965-A1 | DRUGS FOR CHRONIC PAIN | NICOX S.A. (FR) | 2004-07-01 | — | — | WO | claimed |
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885KDM4E 1944/4885HSD17B10 288/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885KDM4E 1944/4885HSD17B10 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.